The National Institutes of Health's National Cancer Institute awarded $331,085.91 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Brigham & Women's Hospital Inc. on February 1, 2021 for completion by September 30, 2022. The project grant funding will support research investigating the role of cellular senescence in chemotherapy-related cognitive impairment and the contribution of microglia to chemotherapy-induced senescence in the brain. Specifically, the grantee will use transgenic mouse models to determine if ablation of senescent cells can rescue cognitive deficits in mice treated with chemotherapy. They will also assess whether pharmacologically depleting microglia can reduce measures of senescence and rescue cognition in a chemotherapy-exposed mouse model of cognitive impairment. Outcomes from this research could inform the development of senolytic therapies to reduce chemotherapy-related morbidity.
Generated 1/6/24, 8:37 PM